Avidity Partners Management
Latest statistics and disclosures from Avidity Partners Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are XBI, Acceleron Pharma, MRTX, ARVN, ABBV, and represent 25.32% of Avidity Partners Management's stock portfolio.
- Added to shares of these 10 stocks: XBI (+$380M), Acceleron Pharma (+$156M), REGN (+$92M), AZN (+$85M), BAX (+$69M), STVN (+$64M), CRBU (+$59M), MRTX (+$55M), OCDX (+$44M), PFE (+$44M).
- Started 23 new stock positions in PFE, RARE, SGHT, STVN, KROS, IOVA, KYMR, FTRP, XBI, SMFR. ALT, ESMT, SLGC, OCDX, KZR, BAX, SLGCW, REGN, AZN, TCRT, RNA, CRBU, TNGX.
- Reduced shares in these 10 stocks: MRVI (-$124M), MDT (-$66M), , NEO (-$62M), , LLY (-$54M), BBIO (-$41M), Trillium Therapeutics, Inc. Cmn (-$40M), , Kadmon Hldgs (-$36M).
- Sold out of its positions in ALDX, TKNO, Bctg Acquisition Corp, BIIB, BBIO, Cm Life Sciences Ii, CRDF, CAH, CELC, CNC.
- Avidity Partners Management was a net buyer of stock by $853M.
- Avidity Partners Management has $4.5B in assets under management (AUM), dropping by 21.99%.
- Central Index Key (CIK): 0001791827
Tip: Access up to 7 years of quarterly data
Positions held by Avidity Partners Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Avidity Partners Management
Companies in the Avidity Partners Management portfolio as of the September 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Spdr Ser Tr S&p Biotech Call Option (XBI) | 8.4 | $380M | NEW | 3.0M | 125.71 | |
| Acceleron Pharma | 4.8 | $217M | +252% | 1.3M | 172.11 | |
| Mirati Therapeutics (MRTX) | 4.2 | $188M | +41% | 1.1M | 176.91 | |
| Arvinas Ord (ARVN) | 4.1 | $184M | +20% | 2.2M | 82.18 | |
| Abbvie (ABBV) | 3.9 | $174M | +8% | 1.6M | 107.87 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 3.7 | $168M | -2% | 926k | 181.39 | |
| Zentalis Pharmaceuticals (ZNTL) | 3.7 | $166M | +15% | 2.5M | 66.64 | |
| Avantor (AVTR) | 2.9 | $133M | +2% | 3.2M | 40.90 | |
| Biohaven Pharmaceutical Holding (BHVN) | 2.9 | $130M | +5% | 934k | 138.91 | |
| Syndax Pharmaceuticals (SNDX) | 2.0 | $92M | +4% | 4.8M | 19.11 | |
| Regeneron Pharmaceuticals (REGN) | 2.0 | $92M | NEW | 152k | 605.18 | |
| Seagen (SGEN) | 2.0 | $91M | -16% | 537k | 169.80 | |
| Horizon Therapeutics Pub L SHS (HZNP) | 2.0 | $91M | +45% | 826k | 109.54 | |
| Blueprint Medicines (BPMC) | 1.9 | $86M | +47% | 832k | 102.81 | |
| Astrazeneca Sponsored Adr (AZN) | 1.9 | $85M | NEW | 1.4M | 60.06 | |
| Neurocrine Biosciences (NBIX) | 1.8 | $81M | +24% | 849k | 95.91 | |
| Alnylam Pharmaceuticals (ALNY) | 1.8 | $81M | +118% | 427k | 188.81 | |
| Eli Lilly & Co. (LLY) | 1.7 | $76M | -41% | 330k | 231.05 | |
| Nuvation Bio Com Cl A (NUVB) | 1.6 | $72M | +4% | 7.3M | 9.94 | |
| Natera (NTRA) | 1.6 | $71M | +46% | 639k | 111.44 | |
| Hologic (HOLX) | 1.5 | $70M | -21% | 945k | 73.81 | |
| Baxter International (BAX) | 1.5 | $69M | NEW | 862k | 80.43 | |
| Arena Pharmaceuticals Com New | 1.5 | $68M | +20% | 1.1M | 59.55 | |
| Iveric Bio (ISEE) | 1.5 | $67M | +192% | 4.1M | 16.24 | |
| United Therapeutics Corporation (UTHR) | 1.4 | $65M | +48% | 351k | 184.58 | |
| Stevanato Group S P A Ord Shs (STVN) | 1.4 | $64M | NEW | 2.5M | 25.31 | |
| Sotera Health (SHC) | 1.4 | $62M | +24% | 2.4M | 26.15 | |
| Ideaya Biosciences (IDYA) | 1.4 | $62M | +17% | 2.4M | 25.49 | |
| Caribou Biosciences (CRBU) | 1.3 | $59M | NEW | 2.5M | 23.87 | |
| Catalent (CTLT) | 1.2 | $53M | -26% | 398k | 133.07 | |
| Gritstone Oncology Ord (GRTS) | 1.1 | $48M | +110% | 4.5M | 10.80 | |
| Legend Biotech Corp Sponsored Ads (LEGN) | 1.0 | $45M | +43% | 894k | 50.56 | |
| Ortho Clinical Diagnostics H Ord Shs (OCDX) | 1.0 | $44M | NEW | 2.4M | 18.48 | |
| Pfizer (PFE) | 1.0 | $44M | NEW | 1.0M | 43.01 | |
| Arrowhead Pharmaceuticals (ARWR) | 0.9 | $42M | +547% | 674k | 62.43 | |
| Shattuck Labs (STTK) | 0.9 | $41M | +4% | 2.0M | 20.38 | |
| Ultragenyx Pharmaceutical (RARE) | 0.9 | $41M | NEW | 455k | 90.19 | |
| Immunocore Hldgs Ads (IMCR) | 0.9 | $41M | +82% | 1.1M | 37.07 | |
| Avidity Biosciences Ord (RNA) | 0.9 | $41M | NEW | 1.6M | 24.63 | |
| Iovance Biotherapeutics (IOVA) | 0.8 | $36M | NEW | 1.5M | 24.66 | |
| Insmed Com Par $.01 (INSM) | 0.8 | $36M | +12% | 1.3M | 27.54 | |
| EXACT Sciences Corporation (EXAS) | 0.8 | $35M | -37% | 369k | 95.45 | |
| Compass Pathways Sponsored Ads (CMPS) | 0.8 | $35M | +16% | 1.2M | 29.87 | |
| Alphatec Hldgs Com New (ATEC) | 0.8 | $34M | +6% | 2.8M | 12.19 | |
| Intellia Therapeutics (NTLA) | 0.7 | $34M | -33% | 251k | 134.15 | |
| I Mab Sponsored Ads (IMAB) | 0.7 | $33M | -37% | 454k | 72.49 | |
| Seaspine Holdings (SPNE) | 0.7 | $31M | +27% | 1.9M | 15.73 | |
| Bellus Health Com New (BLU) | 0.7 | $30M | +16% | 4.9M | 6.14 | |
| Kymera Therapeutics (KYMR) | 0.7 | $30M | NEW | 515k | 58.74 | |
| Cyteir Therapeutics (CYT) | 0.7 | $30M | -6% | 1.7M | 17.55 | |
| Altimmune Com New (ALT) | 0.5 | $25M | NEW | 2.2M | 11.31 | |
| Vir Biotechnology (VIR) | 0.5 | $22M | +217% | 515k | 43.52 | |
| Alpine Immune Sciences (ALPN) | 0.5 | $21M | +29% | 1.9M | 10.67 | |
| Essa Pharma Com New (EPIX) | 0.4 | $20M | -10% | 2.5M | 8.00 | |
| Adicet Bio (ACET) | 0.4 | $19M | +7% | 2.4M | 7.84 | |
| Century Therapeutics (IPSC) | 0.4 | $19M | -26% | 739k | 25.16 | |
| Si-bone (SIBN) | 0.4 | $18M | +44% | 831k | 21.42 | |
| Sana Biotechnology (SANA) | 0.4 | $17M | 775k | 22.52 | ||
| Uipath Cl A (PATH) | 0.4 | $17M | +6% | 319k | 52.61 | |
| Field Trip Health Ord (FTRP) | 0.4 | $16M | NEW | 3.6M | 4.59 | |
| Lifestance Health Group (LFST) | 0.3 | $15M | -9% | 1.0M | 14.50 | |
| Phasebio Pharmaceuticals (PHAS) | 0.3 | $14M | +2% | 4.4M | 3.11 | |
| Sema4 Holdings Corp Com Cl A (SMFR) | 0.3 | $13M | NEW | 1.7M | 7.59 | |
| Gh Research Ordinary Shares (GHRS) | 0.3 | $12M | 560k | 22.06 | ||
| Graphite Bio (GRPH) | 0.3 | $12M | 749k | 16.39 | ||
| Ac Immune Sa SHS (ACIU) | 0.3 | $12M | +9% | 1.7M | 6.71 | |
| Scynexis Com New (SCYX) | 0.2 | $11M | 2.1M | 5.30 | ||
| Werewolf Therapeutics (HOWL) | 0.2 | $11M | -3% | 625k | 17.16 | |
| Sentinelone Cl A (S) | 0.2 | $11M | 200k | 53.57 | ||
| Harpoon Therapeutics (HARP) | 0.2 | $9.4M | -20% | 1.2M | 7.90 | |
| Engagesmart Common Stock (ESMT) | 0.2 | $9.4M | NEW | 275k | 34.06 | |
| ACADIA Pharmaceuticals (ACAD) | 0.2 | $9.1M | -41% | 550k | 16.61 | |
| Orchard Therapeutics Ads (ORTX) | 0.2 | $8.8M | 3.8M | 2.30 | ||
| Caremax Com Cl A (CMAX) | 0.2 | $8.0M | 827k | 9.66 | ||
| Zeta Global Holdings Corp Cl A (ZETA) | 0.2 | $7.6M | 1.3M | 5.86 | ||
| Instil Bio (TIL) | 0.2 | $7.3M | +2% | 408k | 17.88 | |
| Monte Rosa Therapeutics (GLUE) | 0.1 | $6.7M | 300k | 22.28 | ||
| Oncosec Medical Incorporated (ONCS) | 0.1 | $6.3M | +5% | 2.9M | 2.13 | |
| Talaris Therapeutics (TALS) | 0.1 | $6.2M | +4% | 455k | 13.56 | |
| Keros Therapeutics (KROS) | 0.1 | $5.7M | NEW | 145k | 39.56 | |
| ZIOPHARM Oncology (TCRT) | 0.1 | $5.5M | NEW | 3.0M | 1.82 | |
| Medicus Sciences Acquisition Cl A Shs (MSAC) | 0.1 | $5.1M | 520k | 9.75 | ||
| Arya Sciences Acqu Corp Iv Cl A (ARYD) | 0.1 | $5.0M | 500k | 10.05 | ||
| Bcls Acquisition Corp Com Cl A (BLSA) | 0.1 | $5.0M | 500k | 9.96 | ||
| Dynamics Special Purpose Cor Class A Com (DYNS) | 0.1 | $5.0M | 500k | 9.94 | ||
| Healthcor Catalio Acqu Corp Cl A Shs | 0.1 | $5.0M | 500k | 9.90 | ||
| Panacea Acquisition Corp Ii Cl A Shs (PANA) | 0.1 | $4.9M | 500k | 9.77 | ||
| Somalogic Class A Com (SLGC) | 0.1 | $4.1M | NEW | 330k | 12.39 | |
| Health Sciences Acq Corp 2 Ord Shs (HSAQ) | 0.1 | $4.0M | 400k | 9.89 | ||
| Helix Acquisition Corp Com Cl A | 0.1 | $3.9M | 400k | 9.85 | ||
| Lifesci Acquisition Ii Corp | 0.1 | $3.9M | 400k | 9.80 | ||
| Tango Therapeutics (TNGX) | 0.1 | $3.9M | NEW | 300k | 12.93 | |
| Zai Lab Adr (ZLAB) | 0.1 | $3.8M | -64% | 36k | 105.39 | |
| Nautilus Biotechnology (NAUT) | 0.1 | $3.7M | -46% | 600k | 6.14 | |
| Sight Sciences (SGHT) | 0.1 | $3.3M | NEW | 145k | 22.70 | |
| Atai Life Sciences Nv SHS (ATAI) | 0.1 | $3.2M | -37% | 219k | 14.79 | |
| Kezar Life Sciences (KZR) | 0.0 | $2.2M | NEW | 260k | 8.64 | |
| Social Cap Suvretta Hlds Crp Class A Ord Shs (DNAA) | 0.0 | $2.0M | 200k | 9.95 | ||
| Social Cap Suvretta Hlds Crp Class A Ord Shs (DNAB) | 0.0 | $2.0M | 200k | 9.88 | ||
| Social Cap Suvretta Hlds Cp Class A Ord Shs (DNAD) | 0.0 | $2.0M | 200k | 9.81 | ||
| Social Cap Suvretta Hld Crpi Class A Ord Shs (DNAC) | 0.0 | $2.0M | 200k | 9.80 | ||
| Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.0 | $253k | 100k | 2.53 | ||
| Somalogic *w Exp 03/01/202 (SLGCW) | 0.0 | $228k | NEW | 66k | 3.45 | |
| Medicus Sciences Acquisition *w Exp 02/12/202 (MSACW) | 0.0 | $41k | 58k | 0.71 |
Past Filings by Avidity Partners Management
SEC 13F filings are viewable for Avidity Partners Management going back to 2019
- Avidity Partners Management 2021 Q3 filed Nov. 15, 2021
- Avidity Partners Management 2021 Q2 filed Aug. 16, 2021
- Avidity Partners Management 2021 Q1 filed May 17, 2021
- Avidity Partners Management 2020 Q4 filed Feb. 16, 2021
- Avidity Partners Management 2020 Q3 filed Nov. 16, 2020
- Avidity Partners Management 2020 Q2 filed Aug. 14, 2020
- Avidity Partners Management 2019 Q4 amended filed June 17, 2020
- Avidity Partners Management 2020 Q1 amended filed June 17, 2020
- Avidity Partners Management 2020 Q1 filed May 15, 2020
- Avidity Partners Management 2019 Q4 filed Feb. 14, 2020